Cadila up 1 per cent on USFDA nod for high blood pressure
Shital Jibhe / 29 Nov 2017
The share price of Cadila Healthcare was quoting Rs. 444.50, up Rs. 3.15 or 0.71 per cent on the BSE at 10:50 hours on Wednesday.
The share price of Cadila Healthcare was quoting Rs. 444.50, up Rs. 3.15 or 0.71 per cent on the BSE at 10:50 hours on Wednesday.
The company has received USFDA approval for Candesartan Cilexetil and hydrochlorothiazide tablets and market its USP in the strengths of 16mg/12.5mg, 32mg/12.5mg and 32mg/25mg.
The drug is prepared by combining an angiotensin II receptor (type AT1) antagonist and a diuretic, hydrochlorothiazide and is used to treat people having high blood pressure.
The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 170 approvals and has so far filed over 300 Abbreviated New Drug Application (ANDA) since the commencement of their business.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.